What's Happening?
Pandorum Technologies, a biotechnology company with operations in India and the United States, has successfully closed an $18 million Series B financing round. This funding aims to advance the clinical
development of the company's disease-modifying, tunable, exosome-based therapies, including Kuragenx. The investment will also support the scaling of global manufacturing and the expansion of operations across the U.S., Japan, and the Middle East. The financing round was led by Protons Corporate, with contributions from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family. Pandorum's proprietary platform integrates biology, engineering, and computation to develop therapies that reprogram pathological tissue states towards functional recovery. The company is focusing on ocular surface diseases and expanding its platform to address systemic conditions affecting the lung, liver, and nervous systems.
Why It's Important?
The funding marks a significant step in the advancement of regenerative medicine, particularly in the treatment of ocular surface diseases such as Stevens–Johnson Syndrome and Neurotrophic Keratitis. Kuragenx, one of Pandorum's therapies, has already received U.S. FDA Orphan Drug Designation, highlighting its potential impact. The investment will enable Pandorum to translate its scientific breakthroughs into practical, disease-modifying therapies, potentially improving treatment outcomes for patients with inflammatory and degenerative diseases. This development could also enhance the company's competitive position in the global biotechnology market, fostering innovation and collaboration across different regions.
What's Next?
Pandorum Technologies plans to implement a globally distributed manufacturing strategy, including a partnership with AGC Biologics for the U.S. and European markets, and a collaboration with Nucelion Therapeutics in India to support supply across the Asia-Pacific region. The company is also exploring potential partnerships in the Middle East. These strategic moves are expected to facilitate the clinical translation of Pandorum's therapies, beginning with single-tissue applications and scaling to multi-tissue repair. The company's focus on expanding its tunable platform to address systemic conditions could lead to new treatment options for a range of diseases, potentially transforming the landscape of regenerative medicine.
